Fig. 1.

Download original image
Fig. 1. Schema of immunotherapeutic modalities for hematologic malignancy. Antibody-based and cell-based immunotherapies including blinatumomab, inotuzumab, and chimeric antigen receptor (CAR) T cell, have been clinically translated (Adopted from Schultz L et al. Hematology Am Soc Hematol Educ Program. 2019;2019:226-32.).
Clin Pediatr Hematol Oncol 2020;27:14-21
© 2020 Clin Pediatr Hematol Oncol